Completed PHASE2 INTERVENTIONAL 4-arm NCT00486876

A Study of 3 Doses of Dextofisopam in Females With Irritable Bowel Syndrome

A Double-Blind, Randomized, Placebo-Controlled Phase 2b Study of 100, 200, and 300 mg BID Dextofisopam in Female Outpatients With Irritable Bowel Syndrome

Sponsor: Pharmos

Conditions Irritable Bowel Syndrome

Interventions Dextofisopam

Updated 7 times since 2017 Last updated: Aug 1, 2011 Started: Jun 30, 2007 Primary completion: Sep 30, 2009 Completion: Oct 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Irritable Bowel Syndrome and is currently completed. Pharmos leads this study, which shows 7 recorded versions since 2007 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jun 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pharmos

Data source: Pharmos

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States , Ann Arbor, United States , Arkansas City, United States , Asheville, United States , Atlanta, United States , Austin, United States , Birmingham, United States , Bristol, United States , Brooksville, United States , Burbank, United States and 60 more locations